Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice

Konishi, Eiji; Kosugi, Saori; Imoto, Jun-ichi

doi:10.1016/j.vaccine.2005.11.002

Cited by 89 publications

(85 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to these examples, several other reports (e.g., [15][16][17]), as well as our own studies found that it is possible to deliver combinations of certain DNA vaccines without interference with the magnitude or breadth of the immune response to the individual components. For example, we found no notable interference in immune responses elicited in animals given a combination of DNA vaccines for Ebola virus, Marburg virus, Venezuelan equine encephalitis virus, and anthrax [18].…”

Section: Discussioncontrasting

confidence: 83%

Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters

Spik

Badger

Mathiessen³

et al. 2008

Vaccine

View full text Add to dashboard Cite

Connie, "Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters" (2008 b s t r a c tTo determine if DNA vaccines for two hantaviruses causing hemorrhagic fever with renal syndrome, Hantaan virus and Puumala virus, are immunogenic when given in combination, we delivered them to hamsters separately or as mixtures by gene gun or by electroporation. Both vaccines elicited neutralizing antibodies when given alone but when they were delivered as a mixture, antibodies to only one of the two hantaviruses could be detected. In contrast, if the DNAs were given as separate vaccinations to a single animal, responses to both were observed. These studies suggest that the two DNA vaccines will need to be given as separate administrations.Published by Elsevier Ltd.

show abstract

Section: Discussioncontrasting

confidence: 83%

Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters

Spik

Badger

Mathiessen³

et al. 2008

Vaccine

View full text Add to dashboard Cite

show abstract

“…DNA immunization with constructs displaying the same antigenic determinants but different secretory capacity allowed us to demonstrate that antigen secretion is indeed an important characteristic to take into consideration for the design of efficient genetic vaccines. This could explain the poor immunological performances of many constructs so far tested (De Paula et al, 2008;Konishi et al, 2006;Lima et al, 2011;Raviprakash et al, 2000). We show that strategies based on chimerism could be used to enhance the antibody response against epitopes that are otherwise poorly secreted.…”

Section: Discussionmentioning

confidence: 96%

“…Although there are a number of studies describing DNA vaccines against dengue Azevedo et al, 2011;Galula et al, 2014;Khanam et al, 2006;Konishi et al, 2006;Ocazionez Jimenez & Lopes da Fonseca, 2000;Prompetchara et al, 2014;Ramanathan et al, 2009;Raviprakash et al, 2001Raviprakash et al, , 2006, to date there has been only one human clinical trial for a dengue DNA vaccine involving a Phase 1 study of a plasmid expressing the PrM and E proteins of DENV1 . In all cases, these vaccines have been proved to be safe and well-tolerated in humans, although low immunogenicity is still a concern associated with genetic vaccines in general (Coban et al, 2011;Danko et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

Secretion of dengue virus envelope protein ectodomain from mammalian cells is dependent on domain II serotype and affects the immune response upon DNA vaccination

Slon-Campos

Poggianella

Marchese

et al. 2015

Journal of General Virology

View full text Add to dashboard Cite

Dengue virus (DENV) is currently among the most important human pathogens and affects millions of people throughout the tropical and subtropical regions of the world. Although it has been a World Health Organization priority for several years, there is still no efficient vaccine available to prevent infection. The envelope glycoprotein (E), exposed on the surface on infective viral particles, is the main target of neutralizing antibodies. For this reason it has been used as the antigen of choice for vaccine development efforts. Here we show a detailed analysis of factors involved in the expression, secretion and folding of E ectodomain from all four DENV serotypes in mammalian cells, and how this affects their ability to induce neutralizing antibody responses in DNA-vaccinated mice. Proper folding of E domain II (DII) is essential for efficient E ectodomain secretion, with DIII playing a significant role in stabilizing soluble dimers. We also show that the level of protein secreted from transfected cells determines the strength and efficiency of antibody responses in the context of DNA vaccination and should be considered a pivotal feature for the development of E-based DNA vaccines against DENV.

show abstract

“…Vaccination is a preventative method that may prove successful, as it has with other infectious diseases (3). Several dengue vaccine candidates are being developed using different approaches, such as live attenuated (4)(5)(6)(7)(8), chimeric (8)(9)(10), recombinant subunit (8,(11)(12)(13)(14), and DNA vaccines (8,(15)(16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity of a Candidate DNA Vaccine Based on the <i>prM/E</i> Genes of a Dengue Type 2 Virus Cosmopolitan Genotype Strain

et al. 2015

Self Cite

View full text Add to dashboard Cite

SUMMARY:The development of a dengue virus vaccine is a major priority in efforts to control the diseases. Several researchers are currently using the Asian 1 and Asian 2 genotypes as vaccine candidates for dengue type 2 virus (DENV-2). However, in this study, we constructed a recombinant plasmid-based prM/E gene, from a DENV-2 Cosmopolitan genotype strain as a dengue DNA vaccine candidate. The protein expression of the recombinant plasmid in CHO cells was analyzed using an enzyme-linked immunosorbent assay, western blotting, and sucrose gradient sedimentation. After being used to immunize ddY mice three times at doses of 25 or 100 mg, the DNA vaccine induced humoral immune responses. There was no difference in the neutralizing antibody titer (focus reduction neutralization test 50z value) of mice immunized with 25 and 100 mg DNA vaccine doses. When challenged with 3 × 10 5 FFU DENV-2, immunized mice could raise anamnestic neutralizing antibody responses, which were observed at day 4 and day 8 post-challenge. Analysis of immunogenicity using BALB/c mice showed that their antibody neutralization titers were lower than those of ddY mice. In addition, the antibodies produced after immunization and challenge could also neutralize a DENV-2 Asian 2 genotype (New Guinea C) strain. Therefore, the DENV-2 Cosmopolitan genotype may be a DENV-2 vaccine candidate.

show abstract

Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice

Cited by 89 publications

References 34 publications

Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters

Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters

Secretion of dengue virus envelope protein ectodomain from mammalian cells is dependent on domain II serotype and affects the immune response upon DNA vaccination

Immunogenicity of a Candidate DNA Vaccine Based on the <i>prM/E</i> Genes of a Dengue Type 2 Virus Cosmopolitan Genotype Strain

Contact Info

Product

Resources

About